NEARLY 40% OF NEW PRODUCTS APPROVED FROM NON TOP PHARMA IN 2014

Findings of new Infographic highlights state of drug approvals in 2014: EU vs USA


NDA Group has launched a new Infographic today which highlights the state of drug approvals in Europe and the USA in 2014. Key findings include the fact that nearly 40% of approved products came from non top pharma companies.

The new Infographic draws on official data released from the EMA and the FDA, and focuses in on the following key findings:

• The differences in drug approvals between the USA (FDA) and the EU (EMA)

• Breaks-out results by therapeutic areas

• Compares the time taken to get drugs approved, and shows the significant difference in drug approval times between the EU and the US

• Shows the percentage of top pharma vs non top pharma in gaining drug approvals

• Breaks-out those that received ‘Special Status’ in the EU and the USA

The data outlined in the Infographic has been analysed in this new article, here.

2013 VS 2014 DATA

This is the second year NDA has gathered this data and created a comparative infographic to show changes in the industry. To see the findings of last year’s infographic, please see here.

ENDS


NDA media contact: Paula Warmer, e: paula.warmer@ndareg.com, m: + 44 (0) 7713 308314

About NDA
NDA is an independent consulting group based in Germany, Sweden, Switzerland, United Kingdom and USA. Its mission is to ensure that good medicines reach patients without unnecessary delay. It accomplishes this by providing the pharmaceutical industry with a comprehensive range of professional services within regulatory affairs, health technology assessment, pharmacovigilance and quality assurance. NDA’s team comprises more than 25% ex-regulators from major EU Agencies, plus two specialist Advisory Boards, consisting of Europe’s leading regulatory and HTA experts. They are there to provide scientific advice to pharmaceutical companies supporting them in gaining fast and constructive assessment of drug approval applications from European regulatory agencies and payer bodies.

The Author

Paula Warmer

Media contact

Read more

Stay up to date

Contact us